A Prospective Triple-blind Randomized Trial on Safety and Efficacy of Abitant in the Prevention of Chemotherapy-Induced Nausea and Vomiting 2 2 Background: Oral Aprepitant, a neurokinin-1 receptor antagonist, is suggested in combination with other antiemetic agents in preventing chemotherapy-induced nausea and vomiting(CINV) associated with emetogenic chemotherapeutic regimens in adolescents, but its efficacy and safety in pediatric patients more than six months are unknown. in this study, we used abitant drug (a generic name of Aprepitant produced by Exir pharmaceutical company) for preventing CINV in children. Methods: In this triple-blind clinical trial, patients aged between 6 months to 15 years were randomly assigned to receive 3 mg/kg (maximum of 120 mg per dose) Abitant 60 minutes before receiving moderate to highly emetogenic chemotherapy and 2 mg/kg (maximum 80 mg per dose) in days 2 and 3 or placebo plus ondansetron. The primary efficacy endpoint was the percentage of patients who obtained complete response (stated as no retching, no vomiting, and no urge for rescue medication) during 25–120 hours (delayed phase) after initiation of emetogenic chemotherapy. The secondary endpoint was the proportion of children who attained complete response throughout the acute (0–24 h) and the total phase(0-120 h). Efficacy and safety analyses were done with randomly assigned patients who received at least one study treatment dose. Results: twelve patients of the Abitant group (66/7%) and 11 patients of the placebo group (64/7%) showed complete response (P=0.186). There was no significant adverse effect observed in both groups. Complete response on day 5 was 83.3% in the Abitant group and 86/7% in the placebo group. Conclusion: The efficacy of a combination of abitant along with ondansetron in controlling CINV was not inferior to the ondansetron alone in our pediatric population study group. 35 39 2020/12/28 1399/10/8 2021/07/10 1400/4/19 Faatemeh Malek Faatemeh Malek Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran fmalek7721@gmail.com Peyman Eshghi Peyman Eshghi Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran Bahador Mirrahimi Bahador Mirrahimi Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran Samin Alavi Samin Alavi Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran Shiva Nazari Shiva Nazari Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran Bibi Shahin Shamsian Bibi Shahin Shamsian Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran Ahmad Reza Shamshiri Ahmad Reza Shamshiri Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Parasto Molaei Tavana Parasto Molaei Tavana Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran dr_p1984@yahoo.com Abitant Antiemetic Children Nausea and vomiting ## ##

Evaluation of Nasopharynx Bleeding after Nasotracheal Intubation in Dental Patients with Corrected Coagulopathy 2 2 Background: Tracheal intubation for general anesthesia induction can be performed via oral or nasal routes. There is a controversy about nasal route especially in children with corrected coagulopathy because of the probable stimulation for bleeding. We aimed to determine naso-pharynx bleeding in patients with corrected coagulopathy after nasotracheal intubation. Methods: This quasi-experimental study, was conducted on 23 children aged 4-16 years with history of treated coagulopathy needing extensive dental treatment scheduled for a general anesthetic session. Bleeding volume was measured by detailing absorbed amount on a 4×4 inch gauze as well as the volume collected in a nasal bleeding collecting bottle for 24 hours and recorded every four hours. Data were analyzed using Friedman test. Results: Scarce nasal bleeding was observed at the nasal intubation site in patients with hemophilia A. No significant differences were observed on nasal bleeding times in the these patients (P=0.583) Conclusion: Nasotracheal intubation can be performed in patients with hemophilia A after stabilization of the coagulation status with no serious risk of bleeding. 40 43 2020/12/282020/05/10 1399/2/21 2021/07/102021/05/29 1400/3/8 Seyed Alireza Mahdavi Seyed Alireza Mahdavi Associate Prof., Anesthesiology Research Center, Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran alirezamahdavi78@gmail.com Masoud Fallahinejad Ghajari Masoud Fallahinejad Ghajari Professor, Dental Research Center, Research Institute of Dental Sciences, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran masoudfallah36@yahoo.com Ghassem Ansari Ghassem Ansari Professor, Dental Research Center, Research Institute of Dental Sciences, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran drgansari@yahoo.com Peyman eshghi Peyman eshghi Professor of Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children`s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran peshghi64@gmail.com Yasaman Rezvani Yasaman Rezvani Assistant Professor, Department of Pediatric Dentistry, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran yrezvani5@gmail.com Coagulopathy Bleeding Nasotracheal intubation General anesthesia ## ##

Existence of Epstein-Barr Virus in the Umbilical Cord and Sera Samples of Healthy Pregnant Women 2 2 Background: Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a known and serious condition for the hematopoietic stem cell transplantation. This study evaluated the prevalence of EBV in umbilical cord samples of healthy pregnant women in Baghdad, Iraq. Methods: 800 umbilical cord blood (UCB) samples were collected from healthy pregnant women. The enzyme linked immunosorbent assay (ELISA) test was conducted to detect IgM and IgG antibodies. The EBV deoxyribonucleic acid (DNA) was detected in the plasma and buffy coat contents using quantitative real-time polymerase chain reaction (RT-qPCR) and nested PCR techniques. Results: Four (IgG-positive), five and six samples were positive in the ELISA, Nested PCR and RT-qPCR assays, respectively. The age of contaminated women included 26-34 years. Notably, in the ELISA method, all the plasma samples were IgM-negative. Conclusion: The existence of EBV among healthy women is a concern and assessment of a larger sample size is necessary to determine large-scale presence of EBV infection. The RT-qPCR exhibited higher sensitivity than ELISA and nested PCR techniques which can be considered as a confirmatory test. For larger sample size investigation, the ELISA method is appropriate as a primary screening test for lower costs. 44 47 2020/12/282020/05/102020/05/31 1399/3/11 2021/07/102021/05/292021/07/4 1400/4/13 Ghaida Raheem Lateef Al-Awsi Ghaida Raheem Lateef Al-Awsi College of Science, University of Al-Qadisiyah, Iraq ghaidaa@gmail.com Shireen Ali Obaid Shireen Ali Obaid Al-Diwaniyah Teaching Hospital, Diwaniyah, Iraq Saade Abdalkareem Jasim Saade Abdalkareem Jasim Al-maarif University College, Al-anbar, Iraq Fadyia Mahdi Alameedy Fadyia Mahdi Alameedy Department of Biology, Kufa, Najaf, Iraq Cord blood hematopoietic stem cell Epstein Barr virus Real time PCR ELISA ## ##

Efficacy of Deferasirox through Bioequivalence Study in Indonesian Healthy Volunteer 2 2 Background: Deferasirox is an orally bioavailable synthetic, tridentate iron chelator that binds iron at a 2:1 ratio. The generic brand for this drug is still not available in Indonesia. We aimed to compare the efficacy between the generic drug and its innovator (Exjade®) by a study of bioequivalence in Indonesia among healthy volunteers. Methods: An open-label, single-dose, two-sequence, randomized two-way crossover study with one-week wash-out period was evaluated in 28 enrolled volunteers. Blood samples were collected up to 60 hours following drug administration. Deferasirox level was determined by HPLC method with ultraviolet detector. The pharmacokinetic parameters tested for bioequivalence assessment were AUC0-t, AUC0-∞, and Cmax. Results: The 90% confidence intervals obtained by analysis of variance for AUC0-t, AUC0-∞, and Cmax were 83.04%-95.53%, 83.18%-98.88%, and 81.67%-105.47%, respectively. These results were all within the range of 80.00-125.00%. Conclusion: Our results indicated that a single dose of 500 mg Deferasirox tablet demonstrated similar bioequivalence in terms of rate and extent of absorpstion to single dose of Exjade® 500 mg tablet. 48 53 2020/12/282020/05/102020/05/312020/05/6 1399/2/17 2021/07/102021/05/292021/07/42021/04/19 1400/1/30 Asti Swari Paramanindita Asti Swari Paramanindita P.T. Clinisindo Laboratories, Jakarta, Indonesia asti.swari@clinisindo.com Yahdiana Harahap Yahdiana Harahap Faculty of Pharmacy, University of Indonesia, Depok Tri Rahayu Wijayanti Tri Rahayu Wijayanti P.T. Clinisindo Laboratories, Jakarta, Indonesia tri.rahayu@clinisindo.com Windy Lusthom Windy Lusthom P.T. Clinisindo Laboratories, Jakarta, Indonesia windy.lusthom@clinisindo.com Budi Prasaja Budi Prasaja Faculty of Pharmacy, University of Indonesia, Depok budi.prasaja@clinisindo.com Evan Widjaja Evan Widjaja Faculty of Pharmacy, University of Indonesia, Depok Monika Sandra Monika Sandra P.T. Clinisindo Laboratories, Jakarta, Indonesia monika.sandra@clinisindo.com Girinanda Puspanegara Girinanda Puspanegara P.T. Novell Pharmaceutical Laboratories, Jakarta, Indonesia Thalassemia major Deferasirox Bioequivalence Iron chelation Pharmacokinetics ## ##

The Study of COVID-19 in an Iranian Family with Sickle Cell Disease 2 2 Coronavirus Disease 2019 (COVID-19) is a significant medical and public health problem in the world. It is believed that it can worsen in extreme conditions. Also, it is suggested that blood disorders such as sickle cell disease (SCD) may increase the risk of COVID-19 symptoms. The present study reports a family facing COVID-19, in which one of two members with SCD presented with fever, repeated cough and dizziness followed by acute chest syndrome leading to death. The remained members that had sickle cell trait manifested mild symptoms based on our findings. Although COVID-19 in individuals with SCD showed an increased risk for COVID19 compared with individuals with sickle cell trait, it seems that SCD cannot lead to worse condition in our patients. 54 57 2020/12/282020/05/102020/05/312020/05/62020/11/11 1399/8/21 2021/07/102021/05/292021/07/42021/04/192021/07/3 1400/4/12 Seyedeh Moloud Rasouli Ghahfarokhi Seyedeh Moloud Rasouli Ghahfarokhi School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Asghar Dasmeh Asghar Dasmeh Unit of Health, Mahshahr petrochemical industries hospital, Bandar Mahshahr, Khuzestan, Iran Amir Yousef Farahmandi Amir Yousef Farahmandi Department of English, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran Azam Khedri Azam Khedri Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran Fatemeh Asadi Fatemeh Asadi Department of Molecular Genetics, Science and Research Branch, Islamic Azad University, Fars, Iran Fahimeh Piryaei Fahimeh Piryaei Department of Molecular Medicine and Genetics, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran Leila Moradi Leila Moradi Department of Epidemiology, School of Public Health, Hamadan University of Medical, Hamadan, Iran COVID-19 Sickle cell disease Outcome ## ##

Giant Chordoma of the Thoracolumbar Spine 2 2 Chordomas are rare tumors from primitive notochord. They are usually located at sacrococcygeal region when it affects the spine. We present a case of giant chordoma in the thoracolumbar spine in Peru. A 43-year-old woman came to the hospital in Huanuco due to back pain and sensorymotor alterations in the lower limbs. Imaging confirmed an unresectable tumor involving the spine. Two years later, she came back with paraplegia, weight loss, severe anemia and complicated urinary tract infection. Magnetic resonance imaging confirmed a mass measuring 15×15×14 cm in T11, T12 and L1 which histopathology was consistent with chordoma. Chordoma is a rare tumor which should be included in the differential diagnosis of spinal tumors. An earlier diagnosis leads to more options of treatments and longer survival. 58 61 2020/12/282020/05/102020/05/312020/05/62020/11/112020/10/6 1399/7/15 2021/07/102021/05/292021/07/42021/04/192021/07/32021/05/3 1400/2/13 Rolig Aliaga-Chavez Rolig Aliaga-Chavez Department of Chief of Oncology’s, Hospital Nacional Arzobispo Loayza, Lima, Perú oncoesperanza@hotmail.com Monica Vidalón-Cuenca Monica Vidalón-Cuenca Universidad Nacional Mayor de San Marcos, Lima - Perú monicavidalonc@gmail.com Oliver Sulca-Huamaní Oliver Sulca-Huamaní Universidad Nacional Mayor de San Marcos, Lima - Perú oliver.sulca37@gmail.com Gloria Mendoza-Soto Gloria Mendoza-Soto Universidad Nacional Mayor de San Marcos, Lima - Perú gloria.mendoza@unmsm.edu.pe Pedro Guerra-Canchari Pedro Guerra-Canchari Universidad Nacional Mayor de San Marcos, Lima - Perú pguerrac100@gmail.com Chordoma Thoracolumbar spine Magnetic resonance imaging ## ##

Triple Drug Iron Chelation Therapy in Thalassemia Major; A Case Report 2 2 Regular packed cell transfusion in patients with thalassemia major leads to iron overload. Chelation therapy is one of the important aspects of thalassemia care as iron overload causes significant cardiac, hepatic, and endocrine dysfunction. We report a case of thalassemia major with severe iron overload causing cardiac and liver dysfunction who benefitted from triple drug chelation therapy. Triple iron chelation therapy in thalassemia major could be suggested in severe iron overload patients. 62 64 2020/12/282020/05/102020/05/312020/05/62020/11/112020/10/62020/05/9 1399/2/20 2021/07/102021/05/292021/07/42021/04/192021/07/32021/05/32021/06/9 1400/3/19 Ramitha R Bhat Ramitha R Bhat Department of Pediatrics, Kasturba Medical College and Manipal Academy of Higher education (MAHE), Mangaluru, India ramitha.rbhat@gmail.com Harshaprasada Lashkari Harshaprasada Lashkari Department of Pediatrics, Kasturba Medical College and Manipal Academy of Higher education (MAHE), Mangaluru, India harsha.pl@manipal.edu Stalin Ramprakash Stalin Ramprakash Aster CMI hospital, Bangalore, India stalin.r@gmail.com Diana Pereira Diana Pereira Regional advanced pediatric care center, Mangaluru, India dp201201@gmail.com5 Thalassemia major Iron overload Chelation therapy Monotherapy Triple iron chelation therapy ## ##

Erythematous Violaceous Nodule as a Diagnostic Key of a Mucinous Lung Adenocarcinoma 2 2 65 66 2020/12/282020/05/102020/05/312020/05/62020/11/112020/10/62020/05/92020/10/20 1399/7/29 2021/07/102021/05/292021/07/42021/04/192021/07/32021/05/32021/06/92021/06/28 1400/4/7 Gimeno Castillo Javier Gimeno Castillo Javier Department of Dermatology, Hospital Universitario Araba, Vitoria, Spain javiergimenocastillo@gmail.com de la Torre Gomar Francisco Javier de la Torre Gomar Francisco Javier Erythematous Violaceous Nodule as a Diagnostic Key of a Mucinous Lung Adenocarcinoma Pérez-Rodriguez Álvaro Pérez-Rodriguez Álvaro Department of Pathology, Hospital Universitario Araba, Vitoria, Spain Adenocarcinoma Diagnosis Lung neoplasms skin neoplasm metastasis. ## ##